CDC25C Antibody

What is CDC25C and what is its role in cell cycle regulation?

CDC25C (Cell Division Cycle 25 homolog C) is a highly conserved dual-specificity phosphatase that plays a crucial role in regulating the cell cycle, particularly the G2/M transition. It functions primarily by dephosphorylating and activating cyclin-dependent kinases (CDKs), specifically Cdk2 and Cdc2 (CDK1), which are essential for cell cycle progression. CDC25C ensures that cells enter mitosis only when fully prepared, thereby maintaining genomic stability. The protein is present in the cytoplasm of asynchronously growing human cells and undergoes dynamic regulation through phosphorylation events .

In the cell cycle regulatory network, CDC25C participates in a positive feedback loop with CDK1. When activated, CDK1 phosphorylates CDC25C at specific sites (such as Thr48 and Thr67), which enhances CDC25C's phosphatase activity. This creates an autoactivation mechanism that rapidly promotes the G2/M transition. In response to DNA damage, checkpoint kinases (CHK1 and CHK2) phosphorylate CDC25C, promoting its binding to 14-3-3 proteins and sequestration in the cytoplasm, thereby preventing cell cycle progression until the damage is repaired .

What types of CDC25C antibodies are commercially available for research?

Several types of CDC25C antibodies are available for research applications, varying in host species, clonality, and conjugation:

Monoclonal antibodies:

• Mouse monoclonal IgG1 kappa antibodies (e.g., H-6 clone), which specifically detect CDC25C of human origin

• Mouse monoclonal antibodies with reactivity to human, mouse, and rat CDC25C (e.g., 66912-1-Ig)

Polyclonal antibodies:

• Rabbit polyclonal antibodies with reactivity to human, mouse, and rat CDC25C (e.g., DF6546)

Conjugated antibodies:
Many CDC25C antibodies are available in both non-conjugated and conjugated forms including:

• Agarose-conjugated for immunoprecipitation

• Horseradish peroxidase (HRP)-conjugated for direct detection in Western blotting

• Fluorophore-conjugated versions (FITC, PE, Alexa Fluor® variants) for immunofluorescence applications

The choice between these options depends on the specific experimental application, required sensitivity, and the target species being studied.

What are the validated applications for CDC25C antibodies?

CDC25C antibodies have been validated for numerous research applications, with specific validation varying by product. The most commonly validated applications include:

Most CDC25C antibodies have been positively validated in multiple cell lines, including HeLa, HepG2, HEK-293, Jurkat, K-562, HSC-T6, PC-12, NIH/3T3, and Raji cells . The optimal dilution should be determined empirically for each experimental system, as sensitivity can vary based on the expression level of CDC25C in different samples.

How can I optimize detection of different CDC25C phosphorylation states?

Detecting specific phosphorylation states of CDC25C requires careful experimental design:

• Phospho-specific antibodies: When available, use antibodies specifically designed to recognize CDC25C phosphorylated at sites such as Thr48, Thr67, Ser122, Thr130, or Ser214, which are key regulatory sites in the N-terminal domain .

• Phosphatase inhibitors: Always include phosphatase inhibitors (such as sodium orthovanadate, sodium fluoride, and β-glycerophosphate) in your lysis buffer to preserve phosphorylation states.

• Phos-tag SDS-PAGE: Consider using Phos-tag™ acrylamide gels, which specifically retard the migration of phosphorylated proteins, allowing separation of different phosphorylated forms of CDC25C.

• 2D gel electrophoresis: This technique separates proteins first by isoelectric point and then by molecular weight, which can resolve different phosphorylated forms of CDC25C.

• Lambda phosphatase treatment: Treat parallel samples with lambda phosphatase as a control to confirm the identity of phosphorylated bands.

• Cell synchronization: Synchronize cells at different cell cycle stages to capture CDC25C at different phosphorylation states. For example, CDC25C is hyperphosphorylated and activated during the G2/M transition, reaching approximately 70 kDa in its active form .

Remember that CDC25C phosphorylation is dynamic and responds to cell cycle position and DNA damage signaling, so experimental timing is crucial for capturing specific phosphorylation states.

What methods are effective for studying CDC25C interactions with cell cycle regulators?

To study CDC25C interactions with other cell cycle regulators such as CDK1, 14-3-3 proteins, CHK1, and CHK2, several approaches are recommended:

• Co-immunoprecipitation (Co-IP): Use an agarose-conjugated CDC25C antibody (e.g., sc-13138 AC) to pull down CDC25C and its binding partners. For maximum efficiency, cross-link the antibody to the agarose beads to prevent antibody co-elution .

• Proximity ligation assay (PLA): This technique allows visualization of protein-protein interactions in situ with high sensitivity and specificity, ideal for studying transient interactions between CDC25C and its regulators.

• Fluorescence resonance energy transfer (FRET): Use fluorescently tagged CDC25C and interaction partners to monitor real-time interactions in living cells.

• Bimolecular fluorescence complementation (BiFC): Split fluorescent protein assays can confirm the interaction and subcellular localization of CDC25C complexes.

• Mass spectrometry after IP: Identify novel interaction partners of CDC25C through immunoprecipitation followed by mass spectrometry analysis.

When studying the CDC25C-14-3-3 interaction specifically, consider using phospho-mimetic or phospho-dead mutants of CDC25C at known 14-3-3 binding sites to elucidate the functional significance of these interactions. This approach is particularly useful when investigating the role of specific phosphorylation events in regulating CDC25C localization and activity during normal cell cycle progression versus DNA damage response .

What controls should I include when using CDC25C antibodies for Western blotting?

Proper controls are essential for reliable CDC25C detection by Western blotting:

Positive controls:

• Lysates from cell lines known to express CDC25C (HeLa, HepG2, HEK-293, Jurkat, K-562)

• Recombinant CDC25C protein (full-length or the domain recognized by your antibody)

Negative controls:

• CDC25C-depleted samples (siRNA or CRISPR knockout)

• Cell lines with naturally low CDC25C expression

• Secondary antibody-only control to assess non-specific binding

Specificity controls:

• Antibody pre-absorption with immunogen peptide (if available)

• Alternative CDC25C antibody recognizing a different epitope to confirm band identity

Loading controls:

• Housekeeping proteins (β-actin, GAPDH, tubulin) to normalize CDC25C levels

• Total protein staining methods (Ponceau S, SYPRO Ruby, Coomassie)

Technical considerations:

• Always run a molecular weight marker to confirm the expected size of CDC25C (53 kDa calculated, but observed range is typically 46-53 kDa)

• Be prepared to detect multiple bands if studying phosphorylated forms or splice variants

• Consider gradient gels (4-15%) for better resolution of post-translationally modified forms

When troubleshooting, note that the molecular weight of CDC25C can vary due to post-translational modifications, especially phosphorylation, which can shift the apparent molecular weight to approximately 70 kDa in its hyperphosphorylated active form .

How should I optimize CDC25C antibody use for immunofluorescence studies?

When using CDC25C antibodies for immunofluorescence microscopy, consider these optimization strategies:

• Fixation method selection:

  • Test both paraformaldehyde (4%) and methanol fixation, as each may better preserve different epitopes

  • For phospho-CDC25C detection, paraformaldehyde with phosphatase inhibitors is generally recommended

• Permeabilization optimization:

  • Test different permeabilization agents (0.1-0.5% Triton X-100, 0.1-0.5% Saponin, or 0.1% SDS)

  • Adjust permeabilization time (5-15 minutes) to optimize antibody access without damaging antigenicity

• Blocking strategy:

  • Use 5-10% normal serum from the species of your secondary antibody

  • Include 0.1-0.3% Triton X-100 in blocking buffer to reduce background

  • Consider adding 1% BSA to reduce non-specific binding

• Antibody selection and dilution:

  • For CDC25C localization studies, fluorophore-conjugated antibodies (FITC, PE, or Alexa Fluor) provide direct detection with reduced background

  • If using unconjugated primary antibodies, test a range of dilutions (start with manufacturer's recommendation)

  • Extend primary antibody incubation time (overnight at 4°C) for weak signals

• Controls to include:

  • Secondary antibody-only control

  • Cells with CDC25C knockdown/knockout

  • Counterstain with DAPI for nuclear localization studies

• Co-staining considerations:

  • For cell cycle studies, co-stain with cyclin B1 or phospho-histone H3 to identify G2/M cells

  • When studying translocation, include markers for nuclear envelope (lamin) or cytoplasmic compartments

Remember that CDC25C localization changes throughout the cell cycle and in response to DNA damage, so synchronizing cells or treating with DNA damaging agents may be necessary depending on your research question .

Why might I observe multiple bands when detecting CDC25C by Western blot?

Multiple bands in CDC25C Western blots are common and can result from several factors:

• Post-translational modifications:

  • Phosphorylation is the most common modification affecting CDC25C mobility

  • Hyperphosphorylated CDC25C (active form) can appear at approximately 70 kDa

  • Different phosphorylation patterns create multiple bands between 46-70 kDa

• Splice variants:

  • CDC25C has multiple splice variants with different molecular weights

  • These variants may be differentially expressed across tissues and cell lines

• Proteolytic processing:

  • CDC25C can undergo regulated proteolysis during cell cycle or apoptosis

  • Sample preparation without proper protease inhibitors may cause artificial degradation

• Cross-reactivity:

  • Some antibodies may cross-react with other CDC25 family members (CDC25A, CDC25B)

  • Verify specificity by comparing patterns in knockdown/knockout samples

• Non-specific binding:

  • Particularly with polyclonal antibodies, binding to unrelated proteins can occur

  • Optimize blocking conditions and antibody dilutions to minimize this issue

To determine which bands represent genuine CDC25C:

• Compare patterns across different CDC25C antibodies recognizing different epitopes

• Use CDC25C-depleted samples as negative controls

• Consider enriching CDC25C through immunoprecipitation before Western blotting

• Examine changes in band patterns after treatments known to modify CDC25C (e.g., nocodazole for mitotic arrest, or DNA damage inducers)

How can I differentiate between CDC25C isoforms in my experiments?

Differentiating between CDC25C isoforms requires strategic experimental approaches:

• Isoform-specific antibodies:

  • When available, use antibodies that specifically recognize unique regions of particular CDC25C splice variants

  • Verify specificity using recombinant isoforms as positive controls

• Molecular weight analysis:

  • Use high-resolution SDS-PAGE (10-12% gels or gradient gels) to separate isoforms based on size differences

  • Include recombinant isoform standards when available

• 2D gel electrophoresis:

  • Separate CDC25C isoforms first by isoelectric point and then by molecular weight

  • Different phosphorylation states will also be resolved by this method

• RT-PCR/qPCR:

  • Design primers specific to unique regions of different CDC25C splice variants

  • Quantify mRNA expression of specific isoforms before protein analysis

• Mass spectrometry:

  • After immunoprecipitation, use mass spectrometry to identify peptides unique to specific isoforms

  • This can also reveal post-translational modifications that distinguish activated forms

• Functional assays:

  • Different CDC25C isoforms may have distinct subcellular localizations or activities

  • Combine localization studies with activity assays to characterize isoform-specific functions

When interpreting results, remember that CDC25C isoform expression can vary with cell cycle stage, cell type, and in response to stress or DNA damage. The relative abundance of isoforms may therefore change under different experimental conditions .

How can CDC25C antibodies be used to study the G2/M checkpoint?

CDC25C antibodies are valuable tools for investigating G2/M checkpoint regulation:

• Monitoring CDC25C phosphorylation status:

  • Track activating phosphorylations (Thr48, Thr67, Ser214) versus inhibitory phosphorylations (Ser216)

  • Use phospho-specific antibodies when available, or detect mobility shifts by Western blot

  • Compare phosphorylation patterns before and after DNA damage or checkpoint activation

• Studying CDC25C localization:

  • Use immunofluorescence with CDC25C antibodies to track subcellular localization

  • CDC25C sequestration in the cytoplasm (bound to 14-3-3 proteins) indicates checkpoint activation

  • Nuclear accumulation suggests checkpoint inactivation and progression toward mitosis

• Analyzing CDC25C-interacting proteins:

  • Use co-immunoprecipitation with CDC25C antibodies to pull down interaction partners

  • Key interactions include 14-3-3 proteins (checkpoint activation), CDK1 (positive feedback), and checkpoint kinases (CHK1/CHK2)

  • Changes in these interactions reveal checkpoint status

• Measuring CDC25C enzymatic activity:

  • After immunoprecipitation with CDC25C antibodies, perform in vitro phosphatase assays

  • Reduced activity correlates with G2 arrest, while increased activity promotes mitotic entry

• Cell synchronization experiments:

  • Synchronize cells at G1/S (using thymidine or aphidicolin)

  • Release and collect samples at intervals to track CDC25C modifications during G2/M transition

  • Compare normal progression with checkpoint-activated conditions

These approaches can be combined to develop a comprehensive understanding of the node-based model of G2 checkpoint regulation, where CDC25C and Wee1 exert opposing influences on CDK1 activity .

What role does CDC25C dysregulation play in cancer, and how can antibodies help study this connection?

CDC25C dysregulation contributes to cancer development and progression through several mechanisms that can be studied using CDC25C antibodies:

• Expression level analysis:

  • Use Western blotting with CDC25C antibodies to compare expression levels between normal and cancer tissues/cells

  • Elevated CDC25C expression is often observed in various cancers and correlates with poor prognosis

  • Quantitative analysis can establish correlations with clinical outcomes

• Subcellular localization studies:

  • Immunohistochemistry and immunofluorescence with CDC25C antibodies can reveal abnormal localization

  • Mislocalization (e.g., constitutive nuclear presence) may indicate checkpoint dysfunction

  • Compare patterns in normal versus cancer tissues to identify cancer-specific alterations

• Post-translational modification analysis:

  • Cancer cells often show aberrant CDC25C phosphorylation patterns

  • Western blotting can detect shifts in phosphorylation status

  • Compare modifications after treatment with chemotherapeutic agents to assess checkpoint functionality

• CDC25C inhibitor studies:

  • CDC25C antibodies can measure the efficacy of CDC25C-targeting cancer therapeutics

  • Monitor changes in CDC25C levels, activity, and downstream effects in response to treatment

  • Identify biomarkers for treatment response

• Genetic instability assessment:

  • CDC25C overactivation can promote premature mitotic entry and genomic instability

  • Correlate CDC25C status with markers of chromosomal abnormalities

  • Study how CDC25C dysregulation affects DNA damage response pathways

Since uncontrolled cell proliferation driven by CDC25C dysregulation is implicated in various cancers, CDC25C antibodies serve as valuable tools for cancer researchers investigating cell cycle checkpoint defects, developing targeted therapies, and identifying potential biomarkers for cancer diagnosis or prognosis .